The Medicines Co. (MDCO)

34.19
1.20 3.64
NASDAQ : Health Technology
Prev Close 32.99
Open 35.00
Day Low/High 33.12 / 36.85
52 Wk Low/High 16.69 / 41.57
Volume 2.90M
Avg Volume 984.90K
Exchange NASDAQ
Shares Outstanding 73.89M
Market Cap 2.45B
EPS -4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)
The Medicines Company To Present At Two Upcoming Investor Conferences

The Medicines Company To Present At Two Upcoming Investor Conferences

The Medicines Company (NASDAQ:MDCO) today announced that the company is scheduled to make presentations at the following June investor conferences: Jefferies 2016 Healthcare Conference - New York City, Tuesday,...

5 Stocks Insiders Are Scooping Up Right Now

5 Stocks Insiders Are Scooping Up Right Now

Insiders at these five companies have been buying shares of their own stock recently. Should you?

The Medicines Company Appoints Tony Kingsley As President And Chief Operating Officer

The Medicines Company Appoints Tony Kingsley As President And Chief Operating Officer

The Medicines Company (NASDAQ:MDCO) has announced the appointment of Tony Kingsley as President and Chief Operating Officer.

The Medicines Company Reports First-Quarter 2016 Business And Financial Results

The Medicines Company Reports First-Quarter 2016 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the first quarter ended March 31, 2016.

The Medicines Company Agrees To Divest Non-Core Cardiovascular Assets To Chiesi Farmaceutici S.p.A.

The Medicines Company Agrees To Divest Non-Core Cardiovascular Assets To Chiesi Farmaceutici S.p.A.

The Medicines Company (NASDAQ:MDCO) today announced that it has entered into a definitive agreement to sell Cleviprex® (clevidipine), Kengreal® (cangrelor) and the Company's rights to Argatroban for Injection to...

The Medicines Company To Present At Bank Of America Merrill Lynch 2016 Health Care Conference

The Medicines Company To Present At Bank Of America Merrill Lynch 2016 Health Care Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Tuesday, May 10, 2016, at 8:00 AM PT (11:00 AM ET).

The Medicines Company To Announce First Quarter Financial Results On May 9, 2016

The Medicines Company To Announce First Quarter Financial Results On May 9, 2016

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for May 9 th at 8:30 a.

FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)

FDA Grants Fast Track Status For Investigational Antibiotic CARBAVANCE® (meropenem-vaborbactam)

The Medicines Company (NASDAQ:MDCO) today announced that the U.S.

The Medicines Company Announces Participation At 2016 European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID) To Be Held April 9-12 In Amsterdam

The Medicines Company Announces Participation At 2016 European Congress Of Clinical Microbiology And Infectious Diseases (ECCMID) To Be Held April 9-12 In Amsterdam

The Medicines Company (NASDAQ:MDCO) today announced that investigators will present data for the Phase 3 investigational agent CARBAVANCE® (meropenem-vaborbactam) on activity against newly discovered BKC-1...

The Medicines Company Announces Participation At 2016 American College Of Cardiology (ACC) Scientific Sessions In Chicago

The Medicines Company Announces Participation At 2016 American College Of Cardiology (ACC) Scientific Sessions In Chicago

The Medicines Company (NASDAQ:MDCO) today announced that investigators will present new analyses from high-risk percutaneous coronary intervention (PCI) patient subgroups from the CHAMPION PHOENIX study with its...

Insider Trading Alert - MDCO, DXCM And WMGI Traded By Insiders

Insider Trading Alert - MDCO, DXCM And WMGI Traded By Insiders

Stocks with insider trader activity include MDCO, DXCM and WMGI

The Medicines Company To Present At Cowen And Company 36th Annual Health Care Conference

The Medicines Company To Present At Cowen And Company 36th Annual Health Care Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston, MA on Wednesday, March 9, 2016, at 8:40 AM EST.

The Medicines Company To Participate In 2016 RBC Capital Markets Global Healthcare Conference

The Medicines Company To Participate In 2016 RBC Capital Markets Global Healthcare Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to participate at the 2016 RBC Capital Markets Global Healthcare Conference in New York, NY on Tuesday, February 23 rd at 8:00am EST.

Medicines (MDCO) Stock Price Target Lowered at Jefferies

Medicines (MDCO) Stock Price Target Lowered at Jefferies

Jefferies decreased its price target on Medicines (MDCO) stock and maintained its ‘buy’ rating.

Medicines Co. (MDCO) Stock Jumping on Q4 Results

Medicines Co. (MDCO) Stock Jumping on Q4 Results

Medicines Co. (MDCO) stock is climbing on Wednesday afternoon following the release of its 2015 fourth quarter results before today’s market open.

The Medicines Company Reports Fourth-Quarter And Full-Year 2015 Business And Financial Results

The Medicines Company Reports Fourth-Quarter And Full-Year 2015 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the fourth quarter and full year ended December 31, 2015.

Clive Meanwell, MD, PhD Receives Dr. Sol J. Barer Award At BioNJ Gala Event

Clive Meanwell, MD, PhD Receives Dr. Sol J. Barer Award At BioNJ Gala Event

The Medicines Company (NASDAQ:MDCO) today announced that its founder and Chief Executive Officer, Clive Meanwell, MD, PhD, has been awarded the 2016 Dr.

The Medicines Company To Announce Fourth Quarter And Full Year 2015 Financial Results On Wednesday, February 17, 2016

The Medicines Company To Announce Fourth Quarter And Full Year 2015 Financial Results On Wednesday, February 17, 2016

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for Wednesday, February 17 th at 8:30 a.

The Medicines Company Appoints Alexander J. Denner, Ph.D. To Its Board Of Directors

The Medicines Company Appoints Alexander J. Denner, Ph.D. To Its Board Of Directors

The Medicines Company (NASDAQ:MDCO) today announced that it has appointed Alexander J.

The Medicines Company To Participate In Leerink Partners 5th Annual Global Healthcare Conference

The Medicines Company To Participate In Leerink Partners 5th Annual Global Healthcare Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to participate at the Leerink Partners 5 th Annual Global Healthcare Conference in New York, NY on Wednesday, February 10 th at 10:40am EST.

The Medicines Company Completes Divestiture Of Its Hemostasis Portfolio To Mallinckrodt Plc

The Medicines Company Completes Divestiture Of Its Hemostasis Portfolio To Mallinckrodt Plc

The Medicines Company (NASDAQ:MDCO) today announced that it has completed the divestiture of its hemostasis portfolio to Mallinckrodt plc.

Medicines (MDCO) Highlighted As Today's Perilous Reversal Stock

Medicines (MDCO) Highlighted As Today's Perilous Reversal Stock

Trade-Ideas LLC identified Medicines (MDCO) as a "perilous reversal" (up big yesterday but down big today) candidate

Why Medicines (MDCO) Stock is Advancing Today

Why Medicines (MDCO) Stock is Advancing Today

Medicines (MDCO) stock is climbing on Wednesday afternoon as the company explores a sale of itself.

Strong On High Volume: Medicines (MDCO)

Strong On High Volume: Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a strong on high relative volume candidate

The Medicines Company Advances Clinical Development Of Investigational First-in-Class PCSK9 Synthesis Inhibitor For Atherosclerotic Cardiovascular Disease (ASCVD)

The Medicines Company Advances Clinical Development Of Investigational First-in-Class PCSK9 Synthesis Inhibitor For Atherosclerotic Cardiovascular Disease (ASCVD)

The Medicines Company (NASDAQ:MDCO) today announced that it has initiated study sites and begun enrolling patients in the ORION-1 Phase 2 study to compare the effect of different doses of ALN-PCSsc given as subcutaneous...

Medicines (MDCO) Stock: Weak On High Volume Today

Medicines (MDCO) Stock: Weak On High Volume Today

Trade-Ideas LLC identified Medicines (MDCO) as a weak on high relative volume candidate

The Medicines Company To Participate In J.P. Morgan 34th Annual Healthcare Conference

The Medicines Company To Participate In J.P. Morgan 34th Annual Healthcare Conference

The Medicines Company (NASDAQ:MDCO) is scheduled to present at the J.

Today's Dead Cat Bounce Stock Is Medicines (MDCO)

Today's Dead Cat Bounce Stock Is Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a "dead cat bounce" (down big yesterday but up big today) candidate

The Medicines Company Agrees To Divest Its Hemostasis Portfolio To Mallinckrodt Plc

The Medicines Company Agrees To Divest Its Hemostasis Portfolio To Mallinckrodt Plc

The Medicines Company (NASDAQ:MDCO) today announced that it has entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company's global portfolio of three...

The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy

The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published In European Heart Journal- Cardiovascular Pharmacotherapy

The Medicines Company (NASDAQ:MDCO) today announced that the European Heart Journal - Cardiovascular Pharmacotherapy has published results of its Phase 1 study for MDCO-216, a compound under development for the reduction...

TheStreet Quant Rating: D (Sell)